Drug reference

Medroxyprogesterone

Progestogen · Sex hormone responsive conditions

Also known as medroxyprogesterone acetate

ProgestogenSex hormone responsive conditions

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Avoid - not indicated during pregnancy

FDA category + note

Mechanism

Medroxyprogesterone acetate (MPA) is a synthetic C-21 progestogen that binds to progesterone receptors, inducing secretory transformation of the estrogen-primed endometrium and suppressing gonadotropin secretion to inhibit ovulation. It also has partial glucocorticoid activity and weak androgenic properties. As depot medroxyprogesterone acetate (DMPA), a single intramuscular injection provides contraception for 3 months through sustained progestational effects including ovulation suppression, cervical mucus thickening, and endometrial atrophy.

Indications

EndometriosisMenorrhagiaSevere dysmenorrhoeaAlleviation of premenstrual symptomsPrevention of miscarriage in women with a history of recurrent miscarriage

Dosing

Adult: concentration of 10.2 g/100 mL (102 g/litre) or less. If the. haemoglobin concentration is more than 10.2 g/100 mL. (102 g/litre), ulipristal acetate may be considered. The use of

Contraindications

Blood pressure above systolic 160 mmHg or diastolic 95 mmHg
Prolonged immobility after surgery or leg injury
Acute or active hepatic disease
Pregnancy
Breastfeeding (avoid until weaning or for 6 months after birth)

Side effects

Serious

Unusual severe, prolonged headache (especially if first time or getting progressively worse)
Sudden partial or complete loss of vision
Sudden disturbance of hearing or other perceptual disorders
Dysphasia
Bad fainting attack or collapse
First unexplained epileptic seizure
Weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body
Hepatitis
Jaundice
Liver enlargement